The global emergence of extended-spectrum beta-lactamase (ESBL)-producing presents a significant public health threat and complicates antibiotic treatment for infections. This study aimed to determine the prevalence of ESBL-producing in a clinical setting, analyze their antimicrobial susceptibility profiles, and characterize both phenotypic and genetic determinants. A total of 507 non-duplicate clinical isolates of were collected between 2019 and 2020, and third-generation cephalosporin resistance was screened by disk diffusion.
View Article and Find Full Text PDF